Serán BioScience, LLC, a drug development partner, has completed two new buildings and began construction of a third facility at its new 100,000 ft² commercial manufacturing campus in Bend, OR. 

The new campus will encompass a 50,000 ft² manufacturing facility, with an adjacent 50,000 ft² space dedicated to specialized packaging and supply chain operations. The expansion is part of Serán’s mission to provide integrated support from first-in-human (FiH) trials through commercial-scale production of small-molecule therapeutics.

Enabled by a new investment from Bain Capital Life Sciences in September 2024, and continuing investment from Vivo Capital, the new site enhances Serán’s services for complex oral solid dosage forms. Specializing in spray drying, particle engineering, and advanced drug formulation, the U.S. facility is purpose-built to produce commercial-scale, non-sterile solid dose products with high scientific rigor and world-wide regulatory compliance.

Adjacent to the new plant, Serán has completed two newly constructed warehouse and light manufacturing buildings totaling 50,000 f^t2. These facilities support advanced materials management, packaging, labeling, and other critical logistics functions for seamless scale-up and supply chain reliability.

Located near Serán’s existing 90,000 ft² clinical development and manufacturing campus, the new commercial site will integrate with the company’s established clinical operations. The Bend campus houses over 190 highly skilled professionals and features 10 specialized buildings equipped with technologies including nano milling, micronization, dry and wet granulation, spray-dried dispersions, twin-screw melt extrusion, among others. These capabilities span the full spectrum of oral solid dose development, from early-phase formulation through clinical trial manufacturing, packaging, and labeling.

“Our investment in commercial manufacturing capabilities is a direct response to the evolving needs of our clients,” said Dan Smithey, CEO of Serán BioScience. “Modern medicines are increasingly complex and thus require specialized development and manufacturing. Pharmaceutical companies are looking for partners who can not only optimize performance at the clinical stage but also deliver scalable solutions that accelerate time-to-market. We are grateful for the partnership with our construction and design partners, Mortenson Construction, CRB Group and Blaise Cacciola (BCA).”